一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CMTM6：非小细胞肺癌的关键预后指标
英文原题：CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer.
查看英文原题
CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
虽然CKLF样MARVEL跨膜结构域包含6（CMTM6）在稳定PD-L1和肿瘤内免疫逃逸中的作用已得到证实，但其在肺癌组织及邻近巨噬细胞中的表达仍不确定。
本研究旨在通过探讨CMTM6在非小细胞肺癌（NSCLC）预后中的作用来阐明这一模糊之处。对141例NSCLC和110例癌旁正常肺组织样本进行免疫组化染色，采用HSCORE系统评估CMTM6表达。有趣的是，NSCLC中CMTM6水平（161.04 86.60）显著高于正常组织（71.20 45.10）（p < 0.001），不仅在癌细胞中检测到，还在巨噬细胞、淋巴细胞和邻近支气管上皮细胞中检测到。按CMTM6水平对患者进行分层，揭示了其高表达与较差的总生存期之间的相关性（p = 0.003），同时与TIL（肿瘤浸润淋巴细胞）相关（p = 0.037），尤其是在TIL增高的情况下。多变量分析确定CMTM6是总生存期的独立预测因子（p = 0.009），提示NSCLC中CMTM6表达升高可能标志着患者预后不良。
展开英文摘要原文
While CKLF-like MARVEL transmembrane domain containing 6 (CMTM6)'s role in stabilizing PD-L1 and immune evasion within tumors is established, its expression in lung cancer tissue and adjacent macrophages remains uncertain. The study aimed to elucidate this ambiguity by investigating CMTM6's role in non-small cell lung cancer (NSCLC) prognosis. Employing immunohistochemical staining on 141 NSCLC and 110 adjacent normal lung tissue samples, CMTM6 expression was evaluated using the HSCORE system. Interestingly, NSCLC exhibited significantly higher CMTM6 levels (161. 04 86. 60) compared to normal tissues (71.
20 45. 10) ( p < 0. 001), detected not only in cancer cells but also in macrophages, lymphocytes, and nearby bronchial epithelial cells. Stratifying patients by CMTM6 levels unveiled a correlation between heightened expression and poorer overall survival ( p = 0.
003), alongside a link to tumor-infiltrating lymphocytes (TIL) ( p = 0. 037), especially in cases with increased TIL. Multivariate analysis identified CMTM6 as an independent predictor of overall survival ( p = 0. 009), implying that elevated CMTM6 expression in NSCLC might signify an adverse prognostic marker for patient outcomes.
论文信息
- 作者
- Dai F、Duan YL、Feng Q、Song SL、Yang JL、Lv T
- 第一作者单位
- College of Chemistry and Environmental Science, Qujing Normal University, Qujing, Yunnan, 655011, China.China
- 通讯作者单位
- College of Biological Resource and Food Engineering, Qujing Normal University, Qujing, Yunnan, 655011, China.China
- 期刊
- Journal of Cancer2024
- 原文标识
- PubMed 38495487 · DOI 10.7150/jca.93733
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →